231 related articles for article (PubMed ID: 20696022)
1. Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action.
Yu J; Zheng C; Ren X; Li J; Liu M; Zhang L; Liang L; Du W; Han ZC
Scand J Immunol; 2010 Sep; 72(3):242-9. PubMed ID: 20696022
[TBL] [Abstract][Full Text] [Related]
2. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
3. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells transduced with lentiviral-mediated RelB-specific ShRNAs inhibit the development of experimental autoimmune myasthenia gravis.
Zhang Y; Yang H; Xiao B; Wu M; Zhou W; Li J; Li G; Christadoss P
Mol Immunol; 2009 Feb; 46(4):657-67. PubMed ID: 19038457
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
[TBL] [Abstract][Full Text] [Related]
6. Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations.
Psaltis PJ; Paton S; See F; Arthur A; Martin S; Itescu S; Worthley SG; Gronthos S; Zannettino AC
J Cell Physiol; 2010 May; 223(2):530-40. PubMed ID: 20162565
[TBL] [Abstract][Full Text] [Related]
7. [The mechanism of prophylactic effects of nasal tolerance with a dual analogue on experimental autoimmune myasthenia gravis in young mice].
Liu SL; Huang Z
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Apr; 10(2):191-4. PubMed ID: 18433545
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.
Kassis I; Grigoriadis N; Gowda-Kurkalli B; Mizrachi-Kol R; Ben-Hur T; Slavin S; Abramsky O; Karussis D
Arch Neurol; 2008 Jun; 65(6):753-61. PubMed ID: 18541795
[TBL] [Abstract][Full Text] [Related]
9. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus.
Schena F; Gambini C; Gregorio A; Mosconi M; Reverberi D; Gattorno M; Casazza S; Uccelli A; Moretta L; Martini A; Traggiai E
Arthritis Rheum; 2010 Sep; 62(9):2776-86. PubMed ID: 20496367
[TBL] [Abstract][Full Text] [Related]
10. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.
Shi FD; Li H; Wang H; Bai X; van der Meide PH; Link H; Ljunggren HG
J Immunol; 1999 May; 162(10):5757-63. PubMed ID: 10229808
[TBL] [Abstract][Full Text] [Related]
12. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles.
Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H
Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms.
Zhu KY; Feferman T; Maiti PK; Souroujon MC; Fuchs S
J Neuroimmunol; 2006 Jul; 176(1-2):187-97. PubMed ID: 16730380
[TBL] [Abstract][Full Text] [Related]
14. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis.
Constantin G; Marconi S; Rossi B; Angiari S; Calderan L; Anghileri E; Gini B; Bach SD; Martinello M; Bifari F; Galiè M; Turano E; Budui S; Sbarbati A; Krampera M; Bonetti B
Stem Cells; 2009 Oct; 27(10):2624-35. PubMed ID: 19676124
[TBL] [Abstract][Full Text] [Related]
15. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H
Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289
[TBL] [Abstract][Full Text] [Related]
16. The effect of CD3-specific monoclonal antibody on treating experimental autoimmune myasthenia gravis.
Xu RN; Wang JN; Chen GJ; Han GC; Wang RX; Shen BF; Li Y
Cell Mol Immunol; 2005 Dec; 2(6):461-5. PubMed ID: 16426497
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report.
Zhou H; Guo M; Bian C; Sun Z; Yang Z; Zeng Y; Ai H; Zhao RC
Biol Blood Marrow Transplant; 2010 Mar; 16(3):403-12. PubMed ID: 19925878
[TBL] [Abstract][Full Text] [Related]
18. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
19. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
20. HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production.
Poussin MA; Goluszko E; David CS; Franco JU; Christadoss P
J Autoimmun; 2001 Nov; 17(3):175-80. PubMed ID: 11712854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
